Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at Immucor Inc BLUD is $331.47 million. BLUD's operating margin for the same period is 39.64%.
The trailing-twelve-month revenue at Neogen Corporation NEOG is $168.17 million. NEOG's ROE for the same period is 13.25%.
The trailing-twelve-month revenue at ABAXIS Inc ABAX is $139.80 million. ABAX's operating margin for the same period is 15.61%.
The trailing-twelve-month revenue at Meridian Bioscience Inc VIVO is $137.81 million. VIVO's PEG ratio is 1.96.
Trading Ideas.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: MarketsTrading IdeasDiagnostic Substances IndustryHealth CareHealth Care EquipmentHealth Care SuppliesHighest Revenuesmall-cap
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in